Tongyu Lin

2.0k total citations
71 papers, 1.1k citations indexed

About

Tongyu Lin is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Tongyu Lin has authored 71 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pathology and Forensic Medicine, 39 papers in Oncology and 17 papers in Genetics. Recurrent topics in Tongyu Lin's work include Lymphoma Diagnosis and Treatment (42 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (15 papers). Tongyu Lin is often cited by papers focused on Lymphoma Diagnosis and Treatment (42 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (15 papers). Tongyu Lin collaborates with scholars based in China, United States and Switzerland. Tongyu Lin's co-authors include Huiqiang Huang, Yabing Cao, Zhongjun Xia, Qingqing Cai, Sheng Ye, Huangming Hong, He Huang, Suxia Lin, Wenqi Jiang and Wei Wang and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Tongyu Lin

68 papers receiving 1.1k citations

Peers

Countries citing papers authored by Tongyu Lin

Since Specialization

Citations

This map shows the geographic impact of Tongyu Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tongyu Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tongyu Lin more than expected).

Fields of papers citing papers by Tongyu Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tongyu Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tongyu Lin. The network helps show where Tongyu Lin may publish in the future.

Co-authorship network of co-authors of Tongyu Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Tongyu Lin. A scholar is included among the top collaborators of Tongyu Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tongyu Lin. Tongyu Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine learning-driven programmed cell death signature for prognosis and drug candidate discovery in diffuse large B-cell lymphoma: Multi-cohort study and experimental validation 2025 ·International Immunopharmacology ·Bin Luo, Le Yu, Wei Zhang, (unknown), (unknown), Huangming Hong, Yi Zhun Zhu, Tongyu Lin	0
2	Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression 2024 ·Genome Medicine ·(unknown), He Huang, Huangming Hong, (unknown), (unknown), (unknown), Jian Xiao, Zhao Wang, Xiaojie Fang, (unknown), Jia‐Xing Yue, Tongyu Lin	6
3	Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma 2024 ·Clinical and Experimental Medicine ·(unknown), Wei Zhang, He Huang, Xiaojie Fang, (unknown), Ying Tian, (unknown), (unknown), (unknown), Le Yu, (unknown), (unknown), Xudong Li, Huangming Hong, Tongyu Lin	3
4	Comprehensive analyses reveal the promising value of gasdermins as prognostic biomarkers and immunotherapeutic targets in head and neck squamous cell carcinoma 2024 ·Heliyon ·(unknown), (unknown), (unknown), Xinyi Deng, Ying Tian, He Huang, Zhao Wang, (unknown), Huangming Hong, Tongyu Lin	1
5	Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group 2023 ·Cancer Medicine ·(unknown), (unknown), Huangming Hong, (unknown), Le Yu, (unknown), Zhihui Zhang, Liqun Zou, Bo Zhu, Hui Zhou, Xianling Liu, Yao Liu, Hongqiang Guo, He Huang, Tongyu Lin	2
6	Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials 2023 ·Oral Oncology ·(unknown), (unknown), (unknown), (unknown), Xinyi Deng, Le Yu, (unknown), (unknown), Huangming Hong, Xiaojie Fang, Zhao Wang, Ying Tian, He Huang, Tongyu Lin	1
7	Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period 2023 ·Frontiers in Immunology ·(unknown), (unknown), (unknown), Xinyi Deng, (unknown), (unknown), Le Yu, Zhao Wang, Xiaojie Fang, Huangming Hong, He Huang, Tongyu Lin	1
8	Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study 2023 ·HemaSphere ·William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tongyu Lin, Xiaonan Hong, (unknown), Tina Nielsen, Andrea Knapp, Michael Herold, Robert Marcus	27
9	A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma 2023 ·Blood ·Huangming Hong, Mingzhi Zhang, Zhigang Peng, Jianzhen Shen, Yue-Rong Shuang, Hui Zhou, Hongqiang Guo, He Huang, Fei Li, Zhengzi Qian, Lihong Liu, Liang Wang, Wei Yang, Liling Zhang, Pengcheng He, Qian Shen, Fugen Li, (unknown), Tongyu Lin	2
10	Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review) 2023 ·International Journal of Oncology ·(unknown), (unknown), Xinyi Deng, (unknown), Yung‐Chang Chen, Zhao Wang, Huangming Hong, He Huang, Tongyu Lin	51
11	BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma 2020 ·Cancer Communications ·Xiao‐Peng Tian, Jun Cai, Shu‐Yun Ma, Yu Fang, Huiqiang Huang, Tongyu Lin, Hui‐Lan Rao, Mei Li, Zhongjun Xia, Tiebang Kang, Dan Xie, Qingqing Cai	19
12	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2 2020 ·Acta Pharmacologica Sinica ·Shu Liu, He Huang, Rongxin Chen, Zhao Wang, (unknown), Peng Chen, Xiaojie Fang, Zhuojia Chen, (unknown), Xia Zhu, (unknown), (unknown), Hongbing Huang, Min Huang, Xueding Wang, Tongyu Lin	5
13	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Yuqin Song, Jianqiu Wu, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu, (unknown), Liling Zhang, Hong‐Wei Xue, Qingyuan Zhang, Weiwei Wang, (unknown), Jifeng Feng, Jun Zhu	109
14	Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma 2019 ·BMC Cancer ·Yabing Cao, (unknown), (unknown), Yan Chen, (unknown), Hao Hu, (unknown), Tongyu Lin	15
15	Platelet-derived alpha-granules are associated with inflammation in patients with NK/T-cell lymphoma-associated hemophagocytic syndrome 2019 ·Cytokine ·(unknown), (unknown), He Huang, Zhao Wang, Xiaojie Fang, Chengcheng Guo, Fangfang Li, Limei Zhang, (unknown), (unknown), Ying Tian, Tongyu Lin	13
16	Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients 2014 ·PLoS ONE ·Yabing Cao, (unknown), (unknown), Sheng Ye, Tongyu Lin	14
17	Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC 2013 ·Journal of Thoracic Oncology ·Chengcheng Guo, Ruping Shao, Arlene M. Correa, Carmen Behrens, Faye M. Johnson, Maria Gabriela Raso, Ludmila Prudkin, Luisa M. Solis, Maria I. Nuñez, Bingliang Fang, Jack A. Roth, Ignacio I. Wistuba, Stephen G. Swisher, Tongyu Lin, Apar Pataer	19
18	Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue type 2011 ·Tumor Biology ·(unknown), Yuanyuan Zhao, Sheng Ye, He Huang, Ying Tian, Qiuliang Wu, (unknown), Tongyu Lin	7
19	Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience 2009 ·International Journal of Hematology ·(unknown), Chengcheng Guo, Yabing Cao, Jian Xiao, Xiaohong Fu, Jiajia Huang, Huiqiang Huang, Zhongzhen Guan, Tongyu Lin	17
20	Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma 2006 ·Cancer ·Yuhong Li, Yifu He, Wenqi Jiang, (unknown), (unknown), Li Zhang, Zhongjun Xia, Xiaofei Sun, Huiqiang Huang, Tongyu Lin, You‐Jian He, (unknown)	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact